Guideline Integration & Payer Engagement

About Agendia

Agendia is a commercial-stage diagnostics company specializing in genomic profiling for early-stage breast cancer. Its core offerings, MammaPrint and BluePrint, analyze tumor biology from a single sample to predict recurrence risk and identify molecular subtypes, aiming to personalize treatment and reduce both under- and over-treatment. Founded in 2005 and headquartered in Amsterdam, the company serves a global market, with its tests supported by extensive clinical validation and inclusion in major oncology guidelines. Agendia operates as a private company, generating revenue from its diagnostic testing services.

Therapeutic Areas

Other Breast Cancer Diagnostics Drugs